Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response

NCT07582887 is registered in ClinicalTrials.gov with Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental as lead sponsor.

NCT NCT07582887
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07582887 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response
Lead sponsor
Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
Phase
Observational
Overall status
Recruiting
Start date
July 15, 2025
Completion date
March 31, 2027
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, drug-related side effects and adverse reactions, metastatic breast cancer, pharmacogenetic variant